-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 15th, the Liaoning Provincial Drug and Medical Consumables Centralized Procurement Network issued a notice that it received an application from Shanghai Pharmaceuticals Holdings Co.
Aliciyuumab is a PCSK9 monoclonal antibody of Sanofi Pharmaceuticals.
At present, domestic PCSK9 monoclonal antibody has not been approved.
Unfortunately, in the 2020 medical insurance catalog adjustment, both Alisiyuumab and Iloyuumab passed the formal review, but ultimately failed to enter the medical insurance through negotiation
According to the "Medical Insurance Drug Catalog Adjustment Work Plan (Draft for Comment)" issued by the Medical Insurance Bureau, this year, enterprises will submit the drug materials involved in the negotiation in July.